



Boston University
Medical Center



Office of the Institutional
Review Board
500 Harrison Ave, Suite 300
Boston, Massachusetts
02118-2526
Tel: 617-638-7207
Fax: 617-638-7234

Title of Study: EVALUATION OF THE OMNI GENERATION II COHORT OF THE FRAMINGHAM HEART STUDY

Protocol Number: H-22681

RE: Continuing Review

Review Type: Full Board

Action: Approved

Date of Action: 09/12/2012

Date of Expiration: 09/11/2013

Funding Source: NIH/National Heart Lung, and Blood Institute (NHLBI)

Award #: NO1-HC-25195 (contract) & 1 R01 HL107385 grant

Protocol Version #: 1.766476

Consent Form(s):

Study Consent From			
Title	Version Number	Version Date	Outcome
5-Omni Gen 2- Cell Line Spanish	Version 1.1	10/03/2011	Approved
Omni2(2) Spanish Consent Form	Version 1.2	07/25/2012	Approved
3-Blood Draw Consent for Cell Line Creation	Version 1.766473.2	10/29/2010	Approved
2-CTADD Omni 2 Exam 2 - Offsite	Version 1.766473.2	10/29/2010	Approved
Omni2(2) English Consent Form	Version 1.766473.3	07/16/2012	Approved

Dear Dr. Philip A. Wolf,

At the 09/12/2012th Panel Purple Institutional Review Board (IRB) meeting, chaired by Dr. Sanford Auerbach, the above referenced protocol was reviewed. It has been determined that this study meets the requirements set forth by the IRB and is hereby approved. This protocol is valid through the expiration date indicated above.

The study may not continue after the approval period without additional IRB review and approval for continuation. You will receive an email renewal reminder notice prior to study expiration; however, it is your responsibility to assure that this study is not conducted beyond the expiration date.

Please note: this approval does NOT represent approval of any aspects of this study that have not been previously approved by the IRB unless they are specifically noted in the amendment description.

Please be aware that only IRB-approved informed consent forms, validated with current approval dates generated by the INSPIR system, may be used when informed consent is required. Any changes to the approved protocol or informed consent documents must be reviewed and approved prior to implementation unless the change is necessary for the safety of subjects.

You must report to the IRB unanticipated problems involving risk to subjects or others according to the process posted on the IRB website (www.bumc.bu.edu/irb). The IRB must also be informed of any new or significant information that might impact a research participant's safety or willingness to continue in your study.

Investigators are required to ensure that all HIPAA requirements have been met prior to initiating this study. Once approved, validated HIPAA forms may be found within INSPIR under Study Documents.

It is the responsibility of the PI to ensure that all required institutional approvals have been obtained prior to initiating any research activities.

Sincerely yours,



Signature applied by Debora Perez on 09/13/2012 02:38:37 PM EDT

IRB Analyst